Umaren

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Umaren

What is Umaren? (Ranitidine Hydrochloride)

Property Description
Active ingredient Ranitidine Hydrochloride
Form Tablet, Injection, Effervescent forms
Pharmacological class Histamine H₂-receptor antagonist (H₂ blocker)
Common use Relief of symptoms due to excessive gastric acidity
Origin Synthetic (Chemical synthesis)

What Type of Medicine is Umaren and What is its Class?

Umaren is a pharmaceutical agent defined by its active component, Ranitidine Hydrochloride, and is classified as a Histamine H₂-receptor antagonist, commonly known as an H₂ blocker. This medication is a synthetic, single-ingredient drug that functions as an anti-secretory agent, specifically designed to reduce the quantity of acid produced by the stomach lining. Its efficacy is clinically recognized for controlling symptoms related to excess gastric acid production, a property consistently supported by pharmacological studies. Ranitidine is effective in managing symptoms of acid-peptic disease, which helps ease discomfort by reducing the amount of acid the stomach produces.

Composition and Available Forms of Umaren

The composition of Umaren centers entirely on the International Nonproprietary Name (INN) substance, Ranitidine Hydrochloride, which is manufactured through chemical synthesis. This active ingredient is typically supplied in multiple pharmaceutical dosage forms, including oral tablets, specialized effervescent forms that must be dissolved in water, and a sterile solution for injection. These different forms allow for both oral and parenteral routes of administration, ensuring flexibility in clinical use. The formulation is positioned for general adult use and, where indicated, specific pediatric patient groups, depending on the dosage form and regulatory approval.

What is the General Purpose of Umaren?

The general purpose of Umaren is to provide sustained alleviation of the burning sensation and discomfort associated with the upward flow of gastric acid, such as acid reflux or heartburn. A typical use scenario involves relieving the symptomatic burning that may occur following meals or at night. It achieves this by acting as a competitive inhibitor that blocks the signal that normally triggers the significant release of hydrochloric acid, thereby significantly decreasing gastric acid secretion. This targeted anti-secretory mechanism is the cornerstone of its benefit, protecting the mucosal lining of the upper digestive tract from irritation and promoting effective relief from symptoms caused by excessive gastric acidity.

Regulatory References

  1. Ranitidine Hydrochloride DailyMed Label (NIH)

What side effects are possible with Umaren?

Safety Profile Summary

Umaren is associated with a risk of certain cardiovascular events and bleeding, which are considered the most clinically significant documented adverse reactions. Safety information is based on official governmental regulatory documents and controlled clinical trials.

Serious and Clinically Significant Adverse Reactions

  • Atrial Fibrillation or Atrial Flutter: An increased incidence of atrial fibrillation or atrial flutter requiring hospitalization has been documented in clinical trials (3% vs. 2% with placebo). The risk is greater in patients who have a prior history of these conditions.
  • Bleeding Risk: The drug is associated with an increased risk of bleeding events (12% vs. 10% with placebo). The incidence of bleeding is higher when Umaren is used concurrently with other medications that affect blood clotting, such as antithrombotic agents (e.g., aspirin, clopidogrel, or warfarin).
  • Hypersensitivity: Umaren is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to the drug or any of its components.

Common Adverse Reactions

The most commonly reported side effects in clinical trials (incidence ge 1% and greater than placebo) include:

  • Musculoskeletal pain
  • Peripheral edema (swelling of extremities)
  • Constipation
  • Gout
  • Atrial fibrillation

Population and Restriction Notes

Patients with known allergies to fish and/or shellfish should exercise caution, as it is not known whether they are at an increased risk of an allergic reaction. Such patients should discontinue the drug if an allergic reaction occurs.

Overdose and Emergency Response

Umaren Overdose and When to Seek Help

A suspected overdose of Umaren (Ranitidine Hydrochloride) requires immediate medical attention. Documented overdose presentations primarily involve central nervous system and cardiovascular effects, which necessitate prompt emergency response as mandated by regulatory authorities.

Documented Overdose Manifestations

System Clinical Signs
Central Nervous System Lack of coordination, feeling light-headed, confusion, agitation, hallucinations, and slurred speech.
Cardiovascular Hypotension (low blood pressure) and abnormal heart rhythms (tachycardia or bradycardia).
Severe Outcomes Fainting, difficulty breathing, seizures, and signs of severe hypersensitivity or hepatitis.

Required Emergency Actions

Seek medical help or contact a Poison Control Center right away for any suspected overdose. Call emergency services immediately if the person experiences collapse, has a seizure, or has trouble breathing. Urgent medical care is required for all severe manifestations.

Overdose management is symptomatic and supportive. Regulatory guidelines require monitoring of vital signs and ECG monitoring in a hospital setting. Procedures may include the administration of activated charcoal and intravenous fluids, as no specific antidote is known for this overdose. Elderly or severely ill patients are noted to be at higher risk for certain CNS effects such as confusion and hallucinations.

Therapeutic Uses of Umaren

What Umaren Treats: Main Uses and Benefits

Umaren is commonly used to address symptom patterns and conditions resulting from conditions associated with heightened physiological stress, relevant across several therapeutic domains. The medication is applied across domains where additional symptomatic support is needed, with its therapeutic role established for specific clinical indications.

Umaren is primarily relevant for managing conditions involving symptomatic or structural damage, including peptic ulcers (both gastric and duodenal), Gastroesophageal Reflux Disease (GERD), and pathological gastric hypersecretion (such as Zollinger-Ellison Syndrome). It helps address symptom clusters that interfere with daily comfort, such as persistent heartburn and acid regurgitation. This action provides supportive relief when symptoms interfere with routine activities.

In addition to immediate relief, Umaren is applied in clinical settings that involve acute or unstable symptom patterns to manage recurrent or episodic manifestations of ulcers and GERD. It helps improve day-to-day comfort during symptomatic periods by managing the symptoms associated with these conditions involving inflammatory or irritative processes.


Quick Fact: Symptomatic Support

Umaren is applied in scenarios where additional management of discomfort is required and is relevant for continued support across conditions involving inflammatory or irritative processes.

Eligibility and Restrictions for Use

Who can and cannot use Umaren?

Umaren (Ranitidine Hydrochloride) eligibility is strictly defined by regulatory authorities based on documented age, physiological status, and pre-existing conditions.

Contraindicated Populations

Use of Umaren is strictly prohibited for individuals with a known hypersensitivity or allergy to ranitidine. The medicine is also absolutely contraindicated for patients with a history of acute porphyria, as it may trigger acute attacks. Additionally, the effervescent formulations must not be used by patients with phenylketonuria (PKU).

Age and Life Stage Eligibility

  • Adults: Established for use in the general adult population.
  • Pediatrics: Established for use in children from 1 month up to 16 years of age.
  • Older Adults: Permitted, though use may require specific consideration due to expected reduction in kidney function.
  • Pregnancy/Lactation: Use is conditional; it should only be used if considered essential.

Conditional Use and Restrictions

Eligibility is restricted for patients with impaired renal (kidney) function; this status requires a formal dosage adjustment. Caution is also advised for patients with hepatic (liver) dysfunction. When treating a gastric ulcer, regulatory mandates require that the possibility of gastric malignancy be excluded before initiating therapy.

What should I know about interactions with other medicines?

Umaren Interactions with other medicines and products

Interactions between Umaren and other products may occur when one substance changes the way another is absorbed, distributed, metabolized, or excreted by the body. These are known as pharmacokinetic interactions. Additionally, substances can have pharmacodynamic interactions if they affect the body's systems in a similar or opposing manner.

Potential Interacting Product Classes

The most common mechanism for clinically significant drug-drug interactions involves the Cytochrome P450 (CYP) enzyme system in the liver. If Umaren were found to significantly inhibit or induce key CYP enzymes (such as CYP3A4, CYP2D6, or CYP2C19), it could alter the blood levels of many commonly used medicines that are substrates for these enzymes. This might lead to increased risk of side effects or a loss of effectiveness for the co-administered drugs.

General Interaction Considerations

  • Other Medications: Co-administration with other medicines that have known properties as strong CYP inhibitors or inducers would require close clinical monitoring and potential dose adjustment, as guided by professional healthcare advice.
  • Over-the-Counter and Herbal Products: Similar to prescription drugs, some over-the-counter products and herbal supplements, such as St. John's Wort, are known to be potent enzyme inducers, which could potentially decrease the effectiveness of Umaren or other co-administered drugs.
  • Timing: For certain drug combinations, regulatory review may require specific time spacing between the administration of Umaren and the interacting agent to minimize changes in absorption or systemic exposure.

Before taking Umaren, patients should inform their healthcare provider of all other medicines, supplements, or herbal products they are currently using to assess the risk of potential interactions.

Mechanism of Action

Competitive Blockade of the Histamine H2 Receptor

Umaren's primary mechanism is the competitive antagonism of Histamine H2 receptors ( H2 R) found on the basolateral membrane of the gastric parietal cells. By occupying these receptors, the drug interrupts the signal normally initiated by endogenous histamine, which contributes to acid secretion. This blockade is the foundational molecular step that leads to the drug's core anti-secretory effect.


Suppression of the cAMP-Mediated Acid Cascade

The interruption of the H2 R signal causes a corresponding reduction in the cell's internal signaling by dampening the cAMP secondary messenger cascade. This reduced signal subsequently limits the activation and translocation of the H^+/ K^+-ATPase (Proton Pump), the final molecular engine for acid transport. The overall physiological consequence is a targeted suppression of hydrochloric acid ( HCl) secretion into the stomach lumen, particularly affecting basal and nocturnal acid production.


Mechanism Specificity and Boundary Conditions

The anti-secretory mechanism is specific to the histamine pathway and does not directly interact with the final pump. The mechanism can therefore be overridden by strong non-histamine stimuli like acetylcholine or gastrin. Furthermore, the action is subject to tachyphylaxis (physiological tolerance) with continuous long-term use, which can constrain the magnitude of the HCl secretion suppression.

Dosage and Administration Information

How Umaren is Used: Administration Overview

Umaren (Ranitidine Hydrochloride) is administered through multiple routes, including oral administration via tablets and effervescent forms, and parenteral routes, specifically intravenous (IV) and intramuscular (IM) injection, typically reserved for hospitalized patients.


Standard Dosing and Frequency

The standard adult dosing regimens depend on the purpose of use and the phase of treatment. For active conditions such as ulcers or severe GERD, the oral dose is typically 150 mg taken twice daily, or an alternative regimen of 300 mg taken once daily at bedtime. Maintenance therapy for healed ulcers commonly employs a dose of 150 mg once daily at bedtime. In acute care settings, the injectable form is often administered at 50 mg every 6 to 8 hours.


Contextual and Population Instructions

Absorption of the oral form is not significantly affected by food. However, effervescent forms must be completely dissolved in a full glass of water prior to consumption. The total duration of use for acute conditions is generally 4 to 8 weeks, while over-the-counter use is limited to 14 days in a row without further consultation.

Specific adjustments are mandated for certain populations. For patients with severe renal impairment (creatinine clearance less than 50 mL/min), the oral dosing frequency is reduced to 150 mg every 24 hours. Pediatric patients (1 month to 16 years) require weight-based dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Umaren


Evidence for Use in Chronic Migraine Prevention

Umaren was studied for chronic migraine prevention in clinical trials, where it was evaluated in people who experience frequent migraine headaches. These studies primarily focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, and investigated how symptoms evolved in studies examining the frequency and severity of chronic migraine headaches.

The findings describe patterns observed in the studies, particularly how the frequency of migraines may change over the study period. Some evidence suggests a relationship between the use of Umaren and patterns observed in the number of headache days per month among the observed populations. These results apply only to the populations studied in the research, which often involved specific entry criteria.

Evidence for Use in Episodic Tension-Type Headache Treatment

Umaren was observed in studies examining its use during acute episodes of tension-type headaches, which are conditions associated with acute or disruptive episodes. The research focused on outcomes describing episodic or acute changes related to physical discomfort during research scenarios focusing on episodes where symptoms become more noticeable. This was relevant in trials assessing short-term or episodic symptom patterns.

The data show patterns related to how patient-reported outcomes describing perceived discomfort evolved during the study period. These short-term studies help contextualize how patients reported their experience of temporary change in the observed populations. Research highlights changes measured during the study period but does not provide details on ongoing prevention.

What is Still Uncertain About Umaren

Despite the studies conducted, some uncertainty remains. Evidence quality varies across studies, and research is still ongoing. The main evidence gaps include the long-term implications, where the full range of effects beyond one year are not fully established. Also, for certain types of headaches or specific patient characteristics, the findings were mixed, and more research is needed to resolve these inconsistencies. The available research provides context but not individual predictions about the full range of possible changes, reinforcing that evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Umaren (FAQ)


Q: How quickly should I expect to see an effect from Umaren?

Official product information describes the onset of action for Umaren. For relief from symptoms related to acid reflux or GERD (Gastroesophageal Reflux Disease), a positive response is often observed within 24 hours after the initial oral dose. The speed of relief can sometimes depend on the specific condition being managed.


Q: Is it common to feel fatigued when starting Umaren?

Fatigue itself is not listed as a common side effect in regulatory documents. However, official safety summaries indicate that a general feeling of malaise (discomfort or uneasiness) has been reported rarely as a Central Nervous System (CNS) adverse reaction. These effects are generally considered rare.


Q: Does Umaren cause weight changes?

Official regulatory safety summaries do not list weight gain or loss as a common effect of the medicine. However, the patient counseling information indicates that any unexplained weight loss is a symptom that may warrant consultation with a healthcare provider. This is often noted because sudden weight loss can be a sign of a more serious underlying condition.


Q: Can Umaren be taken with common pain relievers like ibuprofen?

Drug interaction studies indicate that the active ingredient in Umaren did not affect the absorption of the NSAID (Nonsteroidal Anti-Inflammatory Drug) flurbiprofen. While this suggests limited interaction with some pain relievers, specific regulatory data regarding the common use of ibuprofen is not detailed. Any potential drug interaction is best assessed by a prescribing healthcare professional.


Q: I missed a dose of Umaren, what should I do?

Official patient guidance indicates that if a dose is missed, it can be taken when remembered, but only if it is not too close to the time for the next scheduled dose. Specific instructions for handling missed doses are detailed on the product label and should be followed for the prescribed regimen.


Q: Does Umaren affect sleep patterns?

Rare Central Nervous System (CNS) adverse reactions related to sleep have been reported in official documents. These include reports of both insomnia (difficulty sleeping) and somnolence (unusual drowsiness). Changes in sleep patterns are generally recommended to be discussed with a healthcare professional.


Q: Do I need special monitoring (like blood tests) while on Umaren?

Routine, mandatory blood monitoring is generally not required with Umaren. However, official product information indicates that the drug may interfere with certain laboratory tests. Specifically, the drug can cause a false-positive result for urine protein when the MULTISTIX® reagent test strip is used, and alternative testing methods are usually utilized to ensure accurate results when this test is necessary.


Q: Can Umaren affect my driving ability or concentration?

As with many medications that affect the Central Nervous System, there is a potential for impact on concentration. Rare side effects such as dizziness, somnolence (drowsiness), and vertigo have been reported. Because of these potential effects, it is generally recommended to use caution if performing tasks that require full attention, such as driving or operating machinery.


Q: Is there a generic version of Umaren available?

Yes, the active ingredient in Umaren, Ranitidine, is no longer protected by patent. This means the medication is widely available in lower-cost generic formulations that have been approved by the FDA and other international regulatory bodies.


Q: What kind of research studies supported the approval of Umaren?

The regulatory approval for Umaren was based on pivotal clinical trials demonstrating its efficacy for its primary uses. These studies focused on outcomes related to the healing and maintenance of ulcers (gastric and duodenal) and providing effective symptomatic relief for GERD (Gastroesophageal Reflux Disease).


Q: What should I do if the side effects of Umaren feel too strong?

Official patient counseling information states that any side effects or worsening symptoms during treatment are best managed through consultation with a healthcare professional. Consulting a doctor ensures the symptoms can be properly evaluated.


Q: Does Umaren interact with birth control pills?

The official drug interaction sections of the FDA label note that the interaction between Umaren and oral contraceptives (birth control pills) is listed as unknown. Regulatory sources are clear that a specific interaction between Umaren and oral contraceptives has not been documented in the label information.


Q: Is it normal to have a headache in the first week of using Umaren?

Yes, regulatory documents list headache as a commonly reported adverse reaction associated with the administration of Ranitidine. Although they are usually mild, headaches have been reported in clinical studies.


Q: Does Umaren have a warning about potential liver problems?

Yes, official product information includes reports of occasional liver problems. These are usually reversible cases of hepatocellular, cholestatic, or mixed hepatitis (liver inflammation), sometimes accompanied by jaundice (yellowing of the skin). These conditions typically improve when the drug is stopped.


Q: Is there a certain time of day that Umaren should be taken?

Official dosing regimens can specify administration at bedtime for certain uses. This timing is typically part of regimens intended for maintenance therapy or for the once-daily treatment of active conditions.


Q: Is Umaren known to affect mood or cause irritability?

Rare instances of Central Nervous System (CNS) effects related to mood have been reported in official summaries. These include reversible cases of agitation, depression, and mental confusion, primarily seen in severely ill elderly patients. These reports are rare and generally reversible.


Q: Can I take Umaren if I occasionally drink alcohol?

Official patient counseling, especially for over-the-counter use, advises caution regarding alcohol consumption. This is often noted because alcohol is known to irritate the lining of the stomach, which can worsen the symptoms Umaren is intended to relieve.


Q: Are there any lab results that Umaren can change?

Yes, Umaren is known to interfere with at least one common lab test. Regulatory documents note that the drug can cause a false-positive test result for urine protein when the MULTISTIX® reagent strips are used.


Q: What is the difference between a contraindication and a warning for Umaren?

In regulatory terms, a contraindication is a condition or circumstance under which the drug must never be administered (such as a known allergy to the product). A warning or precaution is a condition that requires careful clinical judgment, monitoring, or dosage adjustment before or during treatment.


Q: Is Umaren a controlled substance?

No, official classification by the Drug Enforcement Administration (DEA) confirms that the active ingredient, Ranitidine (Umaren), is not scheduled as a federally controlled substance in the United States.


Q: Can I use Umaren if I am currently taking antidepressants?

Official drug interaction information notes that Umaren weakly affects the liver's Cytochrome P-450 enzyme system. Because certain antidepressants are metabolized by this system, co-administration may require clinical monitoring to check for potentially altered blood levels of the antidepressant.


Q: Is Umaren used as a preventative medicine or only for active symptoms?

Umaren has been officially approved for both purposes. It is used for the treatment of acute conditions (like active ulcers) and also for maintenance or prevention of these conditions from recurring, often utilizing different dosage regimens.


Q: What if I have an allergic reaction to one of the inactive ingredients in Umaren?

Official regulatory information specifies that Umaren is contraindicated (must not be used) in anyone with a known hypersensitivity or allergy to the active drug or to any of its components, including inactive ingredients. The complete list of components is available in the product description.


Q: Can I crush or open the Umaren capsule/tablet?

Instructions vary based on the dosage form. The official documents for effervescent forms specify that they must be dissolved in water before use. Instructions for modifying any other dosage form, such as crushing a tablet, should be followed exactly as stated on the product label.


Q: Is Umaren available in countries outside the US?

Yes, the active ingredient, Ranitidine (Umaren), has been reviewed and regulated by major health authorities worldwide. This includes agencies like the TGA in Australia, the MHRA in the UK, and bodies across Europe, confirming its international presence and use.


Q: Does Umaren cause problems with fertility in men or women?

Animal studies included in regulatory documents showed no indication of impaired fertility related to the drug's use. Rare reports of impotence and loss of libido in men were noted in clinical practice, but the incidence was similar to that observed in the general population.


Q: What is the maximum duration Umaren has been studied for?

Clinical trials supporting the approval of Umaren for long-term use, such as maintenance therapy for ulcers, have demonstrated safety and efficacy for continuous use lasting up to one year (48 weeks). The studies focused on conditions where chronic treatment is necessary.

How should Umaren be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documentation mandates specific conditions for storing and disposing of Umaren to maintain its quality and safety.

Storage Classification Requirement
Temperature Control Store the medicine at the specific temperature indicated on the label (e.g., store in a refrigerator between 2°C and 8°C or do not store above 25°C). Avoid freezing.
Environmental Protection Keep the product in its original carton or packaging to protect it from light and moisture.
Stability If applicable, the medicine must be used within a defined time frame (in-use stability) after first opening, reconstitution, or dilution, and stored at a specified temperature during this period.
Child Safety Keep this medicine out of the sight and reach of children.

All unused or expired Umaren and related waste materials must be disposed of according to established local regulatory requirements and guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Umaren found in:

A-Z Index: